Neurokine Pharmaceuticals Inc.
OTC Bulletin Board : NEUKF

Neurokine Pharmaceuticals Inc.

December 06, 2010 09:02 ET

Neurokine Announces New CFO

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 6, 2010) - Neurokine Pharmaceuticals Inc. (OTCBB:NEUKF) is pleased to announce the appointment of Moira Ong, CA, CFA, to position of Chief Financial Officer. Ms. Ong has more than 10 years experience in public company accounting and audit reporting. From 2005 until 2010, Ms. Ong was the senior Manager at Grant Thornton, LLP in charge of completion of financial statements for Canadian publicly listed companies. From 2003 to 2005 she served as Financial Consultant for strategic Income Security Services. Ms. Ong was the manager of Banking and Securities at Deloitte & Touche LLP in New York from 2000 to 2003 and served as the Senior Accountant for Grant Thornton LLP from 1996 to 2000. Ms. Ong obtained her CA designation in 1999 and her CFA designation in 2003.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to continue to expand its operations, the level of costs incurred in connection with Neurokine's expansion efforts, economic conditions in the industry and the financial strength of Neurokine's customers and suppliers. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • Neurokine Pharmaceuticals Inc.
    Ahmad Doroudian, Ph.D.
    President and CEO
    (604) 805-7783
    www.neurokine.com